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Severe Thrombocytopenia in a Man with Prostatic Cancer
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Saeed Hamid, Ata Khan, Haleem Khan, Roger Sutton, Ikram A. Burney, Mohammed Khurshid ( Department of Medicine
and Pathology, Aga Khan University Hospital, Karachi. )

A 66 year old gentleman was diagnosed to have metastatic adenocarcinoma of the prostate in 1990,
following a CT scan of the abdomen and trans-uretheral resection of prostate (TLJRP). He was started
on estrogen therapy (Fosfesterol sodium). Two years later he presented to the emergency room with
breathlessness and edema of the left ann of a week’s duration. He admitted to persistence of symptoms
of pmstatism and was found to have bilateral axillary lymphadenopathy and pitting edema of the left
arm. A doppler scan revealed left subclavian vein thrombosis. The patient was started on i.v. heparin
and was maintained on it until the resolution of arm edema and was subsequently switched to oral
anticoagulation. The serum Prostate Specific Antigen (PSA) level was found to be 1460 ng/ml.
Fosfesterol was discontinued and the patient was started on antiandrogen therapy (Cyproterone
acetate). The patient was sent home on anticoagulation, but had to be readmitted shortly thereafter
because of the sudden onset of shortness of breath. This time he was found to have bilateral pitting
pedal edema and :tenderness in the right calf. Intravenous heparin was reinstituted. An infçrior
venacavagram revealed extensive thrombosis of the right popliteal vein and the left common iliac vein.
A clinical diagnosis of pulmonary embolism was made. Despite continuous i.v. heparin in adequate
doses, the patient experienced recurrent episodes of shortness of breath. A greenfield filter was placed
in the inferior vena cava to prevent further episodes of pulmonary embolism. The patient remained
heparinized for more than two weeks, until complete resolutionofsyniptoms had occured. Subsequently
oral anticoagulation was started and the dose of coumarin was adjusted to maintain an international
normalized ratio (INR) between 1.8 and2.0.
Over the next several months, the patient was followed up in the oncology clinic with serial
measurements of PSA. Despite being on maximum doses of cyproterone acetate, the PSA level. did not
normalize. Cyproterone was discontinued and the patient was started on the non-progestational anti-androgen flutamide. However, the PSA values continued to fluctuate and subsequently started to increase.
The serum testosterone level was found to be high (235 ng/dl). The corresponding PSA level was 936
ng/ml. The patient was advised to have a subcapsularorchidectomy. He was admitted to the hospital,
where the following laboratory values were obtained: Hb 10.1 gm/dl; TLC 5.7x109/l; platelets
147x109/L; PT 19/12 seconds (INR 1.9); and APTF 34/3 2 seconds. Coumann was stopped and heparin
was started. On the 4th day, the platelet count was found to be 16x109/L. This was rechecked and was
found to be the same. The PT, APT!’ and FDP were all found to be within normal !imits. At this time,
them was no purpura. The next day, ecchymoses had appeared and the platelet count had dropped to
7x109/L and subsequently to 146x109/L after another two days. The plan for subcapsular orchidectomy
was cancelled and the LHRH analogue (Buserelin) was injected subcutaneously. Because of the
relationship of the onset of thrombocytopenia and its resolution, to the start and discontinuation of
heparin, a diagnosis of heparin-induced thrombocytopenia was entertained. Two weeks later, the patient
was readmitted with calf tenderness and left leg edema. He was again found to have deep venous
thrombosis, extending from the popliteal to the external iliac vein. Since the patient was already taking
coumarin, which proved ineffective in preventing thrombus formation, the patient was started on low
molecular weight heparm (LMWH) and aspirin. Presently, the patient is doing well, the symptoms have
largely resolved and the platelet counts, repeated on several occasions, have remained within normal
limits.

Discussion
Thrombocytopenia is one of the most common and important immunological complications of heparin
therapy’. The attendant morbidity and mortality is significant2,3. The incidence of the complication is
1-5%; higher with bovine than with porcine heparin4. Two clinical types have been described; a mild,
early onset type and a severe, delayed onset type5. In the former type, the platelet count does not fall
below 100x109/L and the patient is usually asymptomatic. The situation is easily reversible without any
specific therapy; the mechanism of thrombocytopenia is unknown. The second type is characterized by
a reduction ‘in the platelet count to usually less than 50x109/L, and it occurs 4-9 days after the onset of
heparin therapy. This type is associated with an increased risk of thrombo-embolic complications and
an immune mechanism is implicated in the pathogenesis6,7,8. Of the various drug-induced
thrombocytopenias, that caused by heparin is different as it is associated with relatively little risk of
bleeding, but a high risk of paradoxical thrombosis involving majorvessels. The thrombo-embolic
complications may manifest as cerebral thrombosis, acute myocardial infarction, recurrent pulmonaiy
emboli, orarterial thrombosis resulting in limb gangrene with a 20% risk of amputation9. The proposed
mechanism of heparin induced thrombocytopema is as follows: IgG antibody forms after several days
of exposure to heparin. The antibodies are not specific for heparin and interact with heparin only in the
presence of platelet factor 4 (PF4)10. The IgG/hepann PF4 immune complexes are formed on the
platelet surface and activate platelets by binding to Fc receptors1,11,12,13. Thrombosis is secondaiy to
platelet activation and endothelial cell injuiy4,13. Although the diagnosis of heparin induced
thrombocytopenia is usually clinical, different laboratory tests can be employed, not only for the
confirmation of the diagnosis, but also for screening agents which could be used as alternatives to
heFarin. In-vitro platelet aggregation is a rapid and simple test9,14,15 14C- serotonin release test is more
sensitive and specific 4,16. Other assays have been developed but have little practical value for routine
diagnosis4. Recognition of the condition requires immediate discontinuation of heparin. Platelet
transfusion should be avoided, as these may precipitate arterial thrombosis. As alternatives to i.v.
heparin for anticoagulation, different agents have been tried. Low molecular weight heparin (LMWH)
has been used frequently, generally with a favourable clinical course. Although there may be 25-60%
cross reactivity between unfractionated heparin and LMWH17, the incidence of heparin induced
thrombocytopenia is significantly low18,19,20. An in-vitro platelet aggregation test may help in selecting
the type of LMWH. Besides LMWH, other treatment options include the use of Heparinoid21, Heparan
sulphateand dermatan sulphate22,. Ancrod, and the placement of inferior vena caval filters23. For
established thrombosis, aspirin, dipyridamole, prostacyclin analogues, fibrinolytic therapy and
plasmapharesis all have been tried4,24 with variable success. Our patient developed severe
thrombocytopenia on the fourth day of heparin therapy and this reversed four days after cessation of the
drug without any specific intervention. The diagnosis was established clinically. The patient had been
heparinized on two previous occasions, and retrospective analysis of records revealed that on one
occasion the platelet count had dropped to 84xl09fL, but reverted spontaneously. With as high an
incidence of HIT as that reported in the literature(l-5%), together with the frequency of heparin use in
clinical practice, physicians need to be aware of this important and potentially life-threatening
complication of heparin therapy. LMWH could be usefully employed instead of unfractionated heparin
and in such cases the probability of cross-reactivity could be decreased by performing a simple in-vitro
platelet aggregation test.
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